Vagifem Vaginal Tablets

Vagifem is a low-dose vaginal tablet containing 10 micrograms of estradiol — the same form of oestrogen that the ovaries produce naturally before the menopause. It's used to treat the symptoms of vaginal and urinary atrophy that develop after the menopause, a cluster of changes now known collectively as the genitourinary syndrome of menopause, or GSM. That includes vaginal dryness, soreness, itching, painful sex, urinary urgency, frequency, and recurrent urinary tract infections. The tablet is inserted directly into the vagina using a small single-use applicator, where it dissolves and releases its dose locally over several hours.

Before the menopause, oestrogen keeps the vaginal and lower urinary tract tissues plump, elastic, and well-lubricated, and it supports the lactobacilli that maintain a healthy acidic vaginal pH. As oestrogen levels fall, those tissues become thinner, drier, and less elastic, the natural lubrication reduces, and the change in pH allows different bacteria to flourish — which is one of the reasons recurrent UTIs become more common in this age group. Vagifem replaces a small amount of oestrogen exactly where it's needed, helping the tissues thicken and rehydrate, restoring elasticity, and shifting the vaginal environment back towards its premenopausal balance. Because the dose is so low and the medicine acts locally, only tiny amounts reach the bloodstream.

This is one of the most important distinctions to understand. Systemic HRT — patches such as Evorel, gels such as Oestrogel, sprays such as Lenzetto, and oral tablets — delivers enough oestrogen into the bloodstream to circulate around the whole body and treat symptoms like hot flushes, night sweats, mood changes, and joint aches. Vagifem is a local treatment: the oestrogen acts on the vaginal and urinary tract tissues directly, with very little reaching the rest of the body. This means Vagifem doesn't generally help with hot flushes or other systemic symptoms, but the systemic risks normally discussed with HRT — blood clots, breast effects, cardiovascular considerations — are also much smaller. Many women use both: a patch or gel for whole-body symptoms, and Vagifem for the genitourinary symptoms that systemic HRT often doesn't fully resolve.

Generally no. With systemic HRT, women who still have a uterus need a progestogen to protect the womb lining from the thickening effect of unopposed oestrogen. With low-dose vaginal oestrogen such as Vagifem, the systemic exposure is so small that this doesn't usually apply, and current UK guidance reflects that. There are exceptions — for example, women using Vagifem alongside other oestrogen products, women with previous endometrial issues, or anyone with unexplained vaginal bleeding — where additional review or progestogen cover may be considered. Any new vaginal bleeding while using Vagifem should always be reported, because it needs to be investigated rather than assumed to be from the medicine.

Each Vagifem dose comes pre-packaged inside a slim disposable applicator that looks a little like a thin tampon applicator. Wash your hands, remove the applicator from its wrapping, and lie down or stand with one foot raised — whatever position feels comfortable. Gently insert the applicator into the vagina until you feel slight resistance, then press the plunger to release the tablet. Withdraw the applicator and dispose of it; it's single-use only. Most women find it easier than vaginal creams because there's no mess, no cream on the underwear, and no need to measure a dose. Bedtime is generally recommended because lying down for several hours afterwards keeps the dissolving tablet in close contact with the vaginal wall.

Treatment usually starts with an induction phase of one tablet daily for two weeks. This higher initial frequency saturates the tissues with oestrogen and produces the noticeable improvement in symptoms most women are looking for. After those first two weeks, you switch to a maintenance phase of one tablet twice a week — most women pick two days, such as Monday and Thursday, and stick to them. This twice-weekly rhythm is enough to keep the tissues healthy long-term without needing daily use.

Most women notice some improvement in dryness and comfort during the initial two-week induction phase, and many feel a meaningful difference within the first month. Full benefit — including reduced soreness during sex, less irritation, and fewer urinary symptoms — typically takes around three months of consistent use. Recurrent UTIs in particular tend to reduce gradually rather than overnight, because the vaginal flora and bladder tissue need time to recover. If you stop Vagifem, symptoms generally return slowly over several months, because the underlying tissue change is ongoing. This is why long-term use is normal rather than exceptional.

Yes, in most cases. Vaginal atrophy is a chronic condition rather than a temporary one, and stopping treatment usually means symptoms gradually return. Long-term maintenance use is widely accepted in UK and international guidance, and many women use Vagifem for years. Annual reviews with your GP or a menopause-aware clinician are sensible to confirm that symptoms remain controlled, that there's no unexplained bleeding, and that the dose is still appropriate. There's no fixed cut-off point at which Vagifem must be stopped.

Most women tolerate Vagifem well, which is part of its appeal. The most commonly reported effects are mild local irritation, itching, or a small amount of vaginal discharge, particularly in the first couple of weeks during the induction phase. Some women notice slight breast tenderness or headaches, although these are uncommon given the low systemic dose. Any new vaginal bleeding while using Vagifem should always be reported to a clinician, as should any unexplained pelvic pain or breast changes — these need to be assessed rather than attributed to the medicine.

Yes, sex is fine. Most clinicians suggest avoiding intercourse on the same night you've inserted a dose — partly because the tablet is still dissolving and may be less effective if displaced, and partly because a small amount of oestrogen may transfer to a partner's skin or, with a male partner, onto the penis. The amount that could transfer is very small, but to minimise it, simply apply Vagifem on nights when sex isn't planned, or allow several hours between application and intercourse. Many women find that painful sex eases significantly within the first few weeks of treatment, which is often the change they were hoping for in the first place.

This is a nuanced area and not a simple yes or no. Many women with a personal history of breast cancer can safely use low-dose vaginal oestrogen such as Vagifem, especially when non-hormonal moisturisers and lubricants haven't given enough relief — but the decision needs to be made jointly with the oncology team. Two factors particularly matter: the type of breast cancer (oestrogen-receptor status), and whether you're currently taking aromatase inhibitors, which work by lowering oestrogen levels throughout the body. Women on aromatase inhibitors are generally advised to be more cautious with vaginal oestrogen than those on tamoxifen, although even here practice is shifting as more reassuring data emerges. The right answer is highly individual, and any breast cancer survivor considering Vagifem should always have the conversation with their oncologist or specialist menopause clinician rather than self-prescribing.

The local oestrogen family includes several similar but not identical options, and each has practical strengths. Vagifem (estradiol tablets) and Ovestin (oestriol cream) both treat the same problem but use slightly different oestrogens — estradiol is the more potent form, while oestriol is a weaker, shorter-acting form. In day-to-day life the bigger differences tend to be practical: Vagifem is dry, mess-free, and uses a slim applicator, which many women prefer; Ovestin is a cream that some women find soothing on already-irritated tissue but messier to apply. There's also Estring, an oestradiol-releasing vaginal ring that sits in place for three months at a time and avoids the need for any twice-weekly application, and Blissel, an estriol gel option. The choice often comes down to convenience, tolerability, and prescriber preference, and switching between them is reasonable if one doesn't suit.

A missed dose during the maintenance phase isn't a concern — apply the next one as scheduled. During the daily induction phase, apply as soon as you remember, unless it's nearly time for the next dose, in which case skip the missed one and continue normally. Don't double up. Missing the occasional dose is unlikely to undo your progress; what matters is the overall pattern of consistent use.

A few situations warrant going back rather than continuing on. Any new vaginal bleeding, unexpected discharge, pelvic pain, breast changes, or symptoms that fail to improve after three months of consistent use all need clinical review. Annual check-ins are sensible even when things are going well, both to confirm the diagnosis and treatment are still appropriate and to discuss whether systemic HRT might add value if other menopausal symptoms are emerging. There's no need to push through quietly if Vagifem isn't quite enough — the right combination of treatments often makes a transformative difference, and most prescribers are happy to refine the plan as your needs change.